In an extension of a phase 2 clinical drug trial, the treatment Stelara showed long-term favorable results for people with active lupus after taking the medication for two years. Both overall disease ...

Please provide your email address to receive an email when new articles are posted on . Selarsdi, an ustekinumab biosimilar, is now approved Crohn’s disease and ulcerative colitis. The drug is ...

The FDA recently approved STELARA, a prescription medication for adults suffering from Crohn’s disease. Here’s what you need to know: 1. STELARA is manufactured by Janssen Biotech. 2. This treatment ...

Dong-A-ST's Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, has won the Food and Drug Administration’s approval. “This FDA approval indicates ...

Jan 23 (Reuters) - Johnson & Johnson JNJ.N on Tuesday reported fourth-quarter profit that was slightly above Wall Street expectations, helped by stronger-than-expected demand for its blockbuster ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara. But with biosimilar versions of the autoimmune blockbuster quickly ...

* The first primary endpoint was clinical remission (per CDAI) at week 24, and the second primary endpoint was endoscopic remission (per SES-CD) at week 48. Non-inferiority was met for the first ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

Johnson & Johnson forecast revenue growth for 2024 that could be as high as 6%, putting much of its focus on expanding its medtech business in cardiovascular, robotics and digital — as well as its ...